Dana-Farber Brigham Cancer Center is ranked #4 as a Best Hospital for cancer care by U.S. News and World Report for 2021-22
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.
Dana-Farber Cancer Institute is having a virtual discussion for cancer patients and survivors about the Covid-19 vaccine on January 27, 2020 at 5 pm.
Dana-Farber Cancer Institute has appointed John Ryan to be its next Senior Vice President, General Counsel and Chief Governance Officer, effective December 14. Ryan has extensive expertise representing health care and life sciences organizations in public company and non-profit settings. He has managed a wide range of legal matters, including medical research and technology, clinical care, IP protection and international expansion.
Dana-Farber Cancer Institute, one of the world’s leading centers of cancer research and treatment, and Quest Diagnostics, (NYSE: DGX), the world’s leading provider of diagnostic information services, announced the start of a new research study that provides free COVID-19 antibody testing to individuals who are at high risk of developing multiple myeloma.
Today’s Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for mantle cell lymphoma (MCL) represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute investigators who helped conduct the decisive clinical trial of the therapy.
Scientists at Dana-Farber Cancer Institute have launched a clinical test of a blood cancer drug in patients infected with the COVID-19 virus.
Dana-Farber and Silverberry Genomix launch the SHE Biobank initiative — a long-term study to investigate the impact of genetic predisposition and environmental exposure to development of disease.
Dana-Farber Cancer Institute will establish the Riney Family Multiple Myeloma Initiative to help improve outcomes and accelerate understanding of the underlying biology for the most challenging types of myelomas, cancers that form in a type of white blood cell called a plasma cell.
A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma.
For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute and other research centers will report today at the ASH Annual Meeting.
A new blood test in development has shown ability to screen for numerous types of cancer with a high degree of accuracy, a trial of the test shows.